Tamoxifen resistance: From cell culture experiments towards novel biomarkers

Pathology Research and Practice

Volumn 211, Issue 3, 2015, Pages 189-197

  Nass, Norbert ^a   Kalinski, Thomas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Advanced glycation end products; Breast cancer; Estrogen receptor; GPER; IGF1 receptor; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL MARKER; DRUG THERAPY; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TUMOR MARKER;

BINDING AFFINITY; BREAST NEOPLASMS; CANCER CELL CULTURE; CANCER MODEL; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOMA CELL LINE; DRUG RESISTANCE; DRUG THERAPY; ESR1 GENE; ESR2 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; FEMALE; GENETICS; HUMANS; METABOLISM; PATHOLOGY; RECEPTORS, ESTROGEN; TAMOXIFEN; THERAPEUTIC USE; TREATMENT FAILURE;

EID: 84952716241     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.01.004     Document Type: Review

References (133)

1. Lim E., Metzger-Filho O., Winer E.P. The natural history of hormone receptor-positive breast cancer. Oncol. Williston Park N. 2012, 26:688-694. (696).
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0.
3. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. 10.1016/S0140-6736(04)17666-6.
4. Davies C., Godwin J., Gray R., Clarke M., Cutter D., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 10.1016/S0140-6736(11)60993-8.
5. Clemons M., Danson S., Howell A. Tamoxifen (Nolvadex): a review. Cancer Treat. Rev. 2002, 28:165-180.
6. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer. 2004, 11:643-658. 10.1677/erc.1.00776.
7. García-Becerra R., Santos N., Díaz L., Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int. J. Mol. Sci. 2012, 14:108-145. 10.3390/ijms14010108.
8. Nawata H., Bronzert D., Lippman M.E. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J. Biol. Chem. 1981, 256:5016-5021.
9. Miller M.A., Lippman M.E., Katzenellenbogen B.S. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells. Cancer Res. 1984, 44:5038-5045.
10. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240:889-895.
11. Ponglikitmongkol M., Green S., Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J. 1988, 7:3385-3388.
12. Burns K.A., Li Y., Arao Y., Petrovich R.M., Korach K.S. Selective mutations in estrogen receptor α D-domain alters nuclear translocation and non-estrogen response element gene regulatory mechanisms. J. Biol. Chem. 2011, 286:12640-12649. 10.1074/jbc.M110.187773.
13. Filgueira C.S., Benod C., Lou X., Gunamalai P.S., Villagomez R.A., Strom A., et al. A screening cascade to identify ERβ ligands. Nucl. Recept. Signal. 2014, 12. 10.1621/nrs12003.
14. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263. 10.1210/endo.139.10.6216.
15. Ng H.W., Perkins R., Tong W., Hong H. Versatility or promiscuity: the estrogen receptors, control of ligand selectivity and an update on subtype selective ligands. Int. J. Environ. Res. Public Health 2014, 11:8709-8742. 10.3390/ijerph110908709.
16. Sommer S., Fuqua S.A.W. Estrogen receptor and breast cancer. Semin. Cancer Biol. 2001, 11:339-352. 10.1006/scbi.2001.0389.
17. Clarke R.B., Anderson E., Howell A. Steroid receptors in human breast cancer. Trends Endocrinol. Metab. TEM 2004, 15:316-323. 10.1016/j.tem.2004.07.004.
18. Kampa M., Notas G., Pelekanou V., Troullinaki M., Andrianaki M., Azariadis K., et al. Early membrane initiated transcriptional effects of estrogens in breast cancer cells: first pharmacological evidence for a novel membrane estrogen receptor element (ERx). Steroids 2012, 77:959-967. 10.1016/j.steroids.2012.02.011.
19. Le Romancer M., Poulard C., Cohen P., Sentis S., Renoir J.-M., Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr. Rev. 2011, 32:597-622. 10.1210/er. 2010-0016.
20. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007, 148:3236-3245. 10.1210/en. 2006-1605.
21. Pedram A., Razandi M., Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol. Baltim. MD 2006, 20:1996-2009. 10.1210/me. 2005-0525.
22. Welsh A.W., Lannin D.R., Young G.S., Sherman M.E., Figueroa J.D., Henry N.L., et al. Cytoplasmic estrogen receptor in breast cancer. Clin. Cancer Res. 2012, 18:118-126. Off. J. Am. Assoc. Cancer Res. 10.1158/1078-0432.CCR-11-1236.
23. Li L., Wang Q., Lv X., Sha L., Qin H., Wang L., et al. Expression and localization of estrogen receptor in human breast cancer and its clinical significance. Cell Biochem. Biophys. 2014, 10.1007/s12013-014-0163-6.
24. Hubbard T., Barker D., Birney E., Cameron G., Chen Y., Clark L., et al. The Ensembl genome database project. Nucleic Acids Res. 2002, 30:38-41.
25. Li L., Haynes M.P., Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4807-4812. 10.1073/pnas.0831079100.
26. Penot G., Le Péron C., Mérot Y., Grimaud-Fanouillère E., Ferrière F., Boujrad N., et al. The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells. Endocrinology 2005, 146:5474-5484. 10.1210/en. 2005-0866.
27. Klinge C.M., Riggs K.A., Wickramasinghe N.S., Emberts C.G., McConda D.B., Barry P.N., et al. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Mol. Cell. Endocrinol. 2010, 323:268-276. 10.1016/j.mce.2010.03.013.
28. Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G., et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000, 19:4688-4700. 10.1093/emboj/19.17.4688.
29. Stevens T.A., Meech R. BARX2 and estrogen receptor-alpha (ESR1) coordinately regulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion. Oncogene 2006, 25:5426-5435. 10.1038/sj.onc.1209529.
30. Ohshiro K., Mudvari P., Meng Q., Rayala S.K., Sahin A.A., Fuqua S.A.W., et al. Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator. Mol. Endocrinol. Baltim. MD 2010, 24:914-922. 10.1210/me. 2009-0413.
31. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem. Biophys. Res. Commun. 2005, 336:1023-1027. 10.1016/j.bbrc.2005.08.226.
32. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-α: hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9063-9068. 10.1073/pnas.0603339103.
33. Lin A.H.Y., Li R.W.S., Ho E.Y.W., Leung G.P.H., Leung S.W.S., Vanhoutte P.M., et al. Differential ligand binding affinities of human estrogen receptor-α isoforms. PLoS ONE 2013, 8:e63199. 10.1371/journal.pone.0063199.
34. Kang L., Zhang X., Xie Y., Tu Y., Wang D., Liu Z., et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol. Endocrinol. Baltim. MD 2010, 24:709-721. 10.1210/me. 2009-0317.
35. El Khissiin A., Journé F., Laïos I., Seo H.S., Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids 2000, 65:903-913.
36. Vranic S., Gatalica Z., Deng H., Frkovic-Grazio S., Lee L.M.J., Gurjeva O., et al. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J. Clin. Pathol. 2011, 64:54-57. 10.1136/jcp.2010.082776.
37. Shi L., Dong B., Li Z., Lu Y., Ouyang T., Li J., et al. Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 2009, 27:3423-3429. Off J. Am. Soc. Clin. Oncol. 10.1200/JCO.2008.17.2254.
38. Zheng Y., Zhang J., Xu Z., Sheng J., Zhang X., Wang H., et al. Quantitative profiles of the mRNAs of ER-α and its novel variant ER-α36 in breast cancers and matched normal tissues. J. Zhejiang Univ. Sci. B. 2010, 11:144-150. 10.1631/jzus.B0900266.
39. Li G., Zhang J., Jin K., He K., Zheng Y., Xu X., et al. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Mol. Oncol. 2013, 10.1016/j.molonc.2013.02.001.
40. Zhang X., Wang Z.-Y. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Endocrinology 2013, 10.1210/en. 2013-1116.
41. Zhang X., Ding L., Kang L., Wang Z.-Y. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS ONE 2012, 7:e30174. 10.1371/journal.pone.0030174.
42. Zhang J., Li G., Li Z., Yu X., Zheng Y., Jin K., et al. Estrogen-independent effects of ER-α36 in ER-negative breast cancer. Steroids 2012, 77:666-673. 10.1016/j.steroids.2012.02.013.
43. Chaudhri R.A., Hadadi A., Lobachev K.S., Schwartz Z., Boyan B.D. Estrogen receptor-alpha 36 mediates the anti-apoptotic effect of estradiol in triple negative breast cancer cells via a membrane-associated mechanism. Biochim. Biophys. Acta 2014, 1843:2796-2806. 10.1016/j.bbamcr.2014.07.019.
44. Pelekanou V., Notas G., Kampa M., Tsentelierou E., Radojicic J., Leclercq G., et al. ERα36, a new variant of the ERα is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids 2012, 77:928-934. 10.1016/j.steroids.2011.12.016.
45. Notas G., Kampa M., Pelekanou V., Troullinaki M., Jacquot Y., Leclercq G., et al. Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells. Mol. Oncol. 2013, 7:595-610. 10.1016/j.molonc.2013.02.012.
46. Lykkesfeldt A.E., Madsen M.W., Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182, 780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994, 54:1587-1595.
47. Thrane S., Lykkesfeldt A.E., Larsen M.S., Sorensen B.S., Yde C.W. Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res. Treat. 2013, 139:71-80. 10.1007/s10549-013-2485-2.
48. Zhang Q.X., Borg A., Wolf D.M., Oesterreich S., Fuqua S.A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997, 57:1244-1249.
49. Robinson D.R., Wu Y.-M., Vats P., Su F., Lonigro R.J., Cao X., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013, 45:1446-1451. 10.1038/ng.2823.
50. Toy W., Shen Y., Won H., Green B., Sakr R.A., Will M., et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45:1439-1445. 10.1038/ng.2822.
51. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000, 60:4026-4029.
52. Carmeci C., Thompson D.A., Ring H.Z., Francke U., Weigel R.J. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997, 45:607-617. 10.1006/geno.1997.4972.
53. Feng Y., Gregor P. Cloning of a novel member of the G protein-coupled receptor family related to peptide receptors. Biochem. Biophys. Res. Commun. 1997, 231:651-654. 10.1006/bbrc.1997.6161.
54. Kvingedal A.M., Smeland E.B. A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. FEBS Lett. 1997, 407:59-62.
55. Takada Y., Kato C., Kondo S., Korenaga R., Ando J. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. 1997, 240:737-741. 10.1006/bbrc.1997.7734.
56. Thomas P., Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid Biochem. Mol. Biol. 2006, 102:175-179. 10.1016/j.jsbmb.2006.09.017.
57. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2006, 2:207-212. 10.1038/nchembio775.
58. Dennis M.K., Burai R., Ramesh C., Petrie W.K., Alcon S.N., Nayak T.K., et al. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 2009, 5:421-427. 10.1038/nchembio.168.
59. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 07:1625-1630. 10.1126/science.1106943.
60. Pietras R.J., Levin E.R., Szego C.M. Estrogen receptors and cell signaling. Science 2005, 310:51-53. (51-53 author reply). 10.1126/science.310.5745.51.
61. Cheng S.-B., Quinn J.A., Graeber C.T., Filardo E.J. Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway,. J. Biol. Chem. 2011, 286:22441-22455. 10.1074/jbc.M111.224071.
62. Broselid S., Berg K.A., Chavera T.A., Kahn R., Clarke W.P., Olde B., et al. G protein-coupled receptor 30 (GPR30) forms a plasma membrane complex with membrane-associated guanylate kinases (MAGUKs) and protein kinase A-anchoring protein 5 (AKAP5) that constitutively inhibits cAMP production. J. Biol. Chem. 2014, 289:22117-22127. 10.1074/jbc.M114.566893.
63. Filardo E.J., Quinn J.A., Frackelton A.R., Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. Baltim. MD 2002, 16:70-84. 10.1210/mend.16.1.0758.
64. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624-632. 10.1210/en. 2004-1064.
65. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. Baltim. MD 2000, 14:1649-1660. 10.1210/mend.14.10.0532.
66. Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S., De Amicis F., et al. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol. Endocrinol. Baltim. MD 2009, 23:1815-1826. 10.1210/me.2009-0120.
67. Vivacqua A., Bonofiglio D., Albanito L., Madeo A., Rago V., Carpino A., et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol. Pharmacol. 2006, 70:1414-1423. 10.1124/mol.106.026344.
68. Ignatov A., Ignatov T., Roessner A., Costa S.D., Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res. Treat. 2010, 123:87-96. 10.1007/s10549-009-0624-6.
69. Lappano R., Pisano A., Maggiolini M. GPER function in breast cancer: an overview. Front. Endocrinol. 2014, 5:66. 10.3389/fendo.2014.00066.
70. Ignatov A., Ignatov T., Weissenborn C., Eggemann H., Bischoff J., Semczuk A., et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res. Treat. 2011, 128:457-466. 10.1007/s10549-011-1584-1.
71. Mo Z., Liu M., Yang F., Luo H., Li Z., Tu G., et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res. BCR 2013, 15:R114. 10.1186/bcr3581.
72. Sjöström M., Hartman L., Grabau D., Fornander T., Malmström P., Nordenskjöld B., et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res. Treat. 2014, 145:61-71. 10.1007/s10549-014-2936-4.
73. Lucki N.C., Sewer M.B. Genistein stimulates MCF-7 breast cancer cell growth by inducing acid ceramidase (ASAH1) gene expression. J. Biol. Chem. 2011, 286:19399-19409. 10.1074/jbc.M110.195826.
74. Kang K., Lee S.B., Jung S.H., Cha K.H., Park W.D., Sohn Y.C., et al. Tectoridin, a poor ligand of estrogen receptor alpha, exerts its estrogenic effects via an ERK-dependent pathway. Mol. Cells. 2009, 27:351-357. 10.1007/s10059-009-0045-8.
75. Pupo M., Pisano A., Lappano R., Santolla M.F., De Francesco E.M., Abonante S., et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ. Health Perspect. 2012, 120:1177-1182. 10.1289/ehp.1104526.
76. Scaling A.L., Prossnitz E.R., Hathaway H.J. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm. Cancer. 2014, 5:146-160. 10.1007/s12672-014-0174-1.
77. Weißenborn C., Ignatov T., Ochel H.-J., Costa S.D., Zenclussen A.C., Ignatova Z., et al. GPER functions as a tumor suppressor in triple-negative breast cancer cells. J. Cancer Res. Clin. Oncol. 2014, 140:713-723. 10.1007/s00432-014-1620-8.
78. Weißenborn C., Ignatov T., Poehlmann A., Wege A.K., Costa S.D., Zenclussen A.C., et al. GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells. J. Cancer Res. Clin. Oncol. 2014, 140:663-671. 10.1007/s00432-014-1598-2.
79. Ariazi E.A., Brailoiu E., Yerrum S., Shupp H.A., Slifker M.J., Cunliffe H.E., et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010, 70:1184-1194. 10.1158/0008-5472.CAN-09-3068.
80. Ignatov T., Weißenborn C., Poehlmann A., Lemke A., Semczuk A., Roessner A., et al. GPER-1 expression decreases during breast cancer tumorigenesis'. Cancer Invest. 2013, 31:309-315. 10.3109/07357907.2013.789901.
81. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392:49-53.
82. Christoforou P., Christopoulos P.F., Koutsilieris M. The role of estrogen receptor β in prostate cancer. Mol. Med. Camb. MA 2014, 20:427-434. 10.2119/molmed.2014.00105.
83. Speirs V., Parkes A.T., Kerin M.J., Walton D.S., Carleton P.J., Fox J.N., et al. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?. Cancer Res. 1999, 59:525-528.
84. Dotzlaw H., Leygue E., Watson P.H., Murphy L.C. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res. 1999, 59:529-532.
85. Vladusic E.A., Hornby A.E., Guerra-Vladusic F.K., Lakins J., Lupu R. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol. Rep. 2000, 7:157-167.
86. Fuqua S.A., Schiff R., Parra I., Friedrichs W.E., Su J.L., McKee D.D., et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 1999, 59:5425-5428.
87. Gustafsson J.A., Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J. Steroid Biochem. Mol. Biol. 2000, 74:245-248.
88. Wimberly H., Han G., Pinnaduwage D., Murphy L.C., Yang X.R., Andrulis I.L., et al. ERβ splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Res. Treat. 2014, 146:657-667. 10.1007/s10549-014-3050-3.
89. Huang B., Omoto Y., Iwase H., Yamashita H., Toyama T., Coombes R.C., et al. Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:1933-1938. 10.1073/pnas.1323719111.
90. Honma N., Horii R., Iwase T., Saji S., Younes M., Takubo K., et al. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol. 2008, 26:3727-3734. 10.1200/JCO.2007.14.2968.
91. Honma N., Takubo K., Akiyama F., Kasumi F., Sawabe M., Arai T., et al. Expression of oestrogen receptor-β in apocrine carcinomas of the breast. Histopathology 2007, 50:425-433. 10.1111/j. 1365-2559.2007.02636.x.
92. Bozkurt K.K., Kapucuoğlu N. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues. Pathol. Res. Pract. 2012, 208:133-139. 10.1016/j.prp.2011.12.015.
93. Ohshiro K., Schwartz A.M., Levine P.H., Kumar R. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS ONE 2012, 7:e30725. 10.1371/journal.pone.0030725.
94. Zhou J., Teng R., Wang Q., Xu C., Guo J., Yuan C., et al. Endocrine resistance in breast cancer: current status and a perspective on the roles of miRNAs (Review). Oncol. Lett. 2013, 6:295-305. 10.3892/ol.2013.1405.
95. Gupta A., Caffrey E., Callagy G., Gupta S. Oestrogen-dependent regulation of miRNA biogenesis: many ways to skin the cat. Biochem. Soc. Trans. 2012, 40:752-758. 10.1042/BST20110763.
96. Maillot G., Lacroix-Triki M., Pierredon S., Gratadou L., Schmidt S., Bénès V., et al. Widespread estrogen-dependent repression of microRNAs involved in breast tumor cell growth. Cancer Res. 2009, 69:8332-8340. 10.1158/0008-5472.CAN-09-2206.
97. Bhat-Nakshatri P., Wang G., Collins N.R., Thomson M.J., Geistlinger T.R., Carroll J.S., et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009, 37:4850-4861. 10.1093/nar/gkp500.
98. Mulrane L., Madden S.F., Brennan D.J., Gremel G., McGee S.F., McNally S., et al. miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin. Cancer Res. 2012, 18:6702-6713. Off. J. Am. Assoc. Cancer Res. 10.1158/1078-0432.CCR-12-1420.
99. Agarwal S., Hanna J., Sherman M.E., Figueroa J., Rimm D.L. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. Br. J. Cancer 2014, 10.1038/bjc.2014.573.
100. Zhou X., Wang X., Huang Z., Xu L., Zhu W., Liu P. An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer. J. Exp. Clin. Cancer Res. CR 2014, 33:94. 10.1186/PREACCEPT-1832455494137554.
101. Ward A., Balwierz A., Zhang J.D., Küblbeck M., Pawitan Y., Hielscher T., et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2012, 10.1038/onc.2012.128.
102. Wei Y., Lai X., Yu S., Chen S., Ma Y., Zhang Y., et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res. Treat. 2014, 147:423-431. 10.1007/s10549-014-3037-0.
103. Gan R., Yang Y., Yang X., Zhao L., Lu J., Meng Q.H. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene. Ther. 2014, 21:290-296. 10.1038/cgt.2014.29.
104. Bai J.-X., Yan B., Zhao Z.-N., Xiao X., Qin W.-W., Zhang R., et al. Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines. Endocrinology 2013, 154:635-645. 10.1210/en. 2012-1607.
105. He Y.-J., Wu J.-Z., Ji M.-H., Ma T., Qiao E.-Q., Ma R., et al. miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer. Exp. Ther. Med. 2013, 5:813-818. 10.3892/etm.2013.915.
106. Ward A., Shukla K., Balwierz A., Soons Z., König R., Sahin O., et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J. Pathol. 2014, 233:368-379. 10.1002/path.4363.
107. Lyng M.B., Lænkholm A.-V., Søkilde R., Gravgaard K.H., Litman T., Ditzel H.J. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. PLoS ONE 2012, 7:e36170. 10.1371/journal.pone.0036170.
108. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M.W., Harper M.E., et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044. 10.1210/en. 2002-220620.
109. Hutcheson I.R., Knowlden J.M., Madden T.-A., Barrow D., Gee J.M.W., Wakeling A.E., et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. Treat. 2003, 81:81-93. 10.1023/A:1025484908380.
110. Hurtado A., Holmes K.A., Geistlinger T.R., Hutcheson I.R., Nicholson R.I., Brown M., et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008, 456:663-666. 10.1038/nature07483.
111. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y.C., Stratford A.L., et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008, 68:10238-10246. 10.1158/0008-5472.CAN-08-2755.
112. Gualberto A., Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr. Drug Targets 2009, 10:923-936.
113. Fox E.M., Miller T.W., Balko J.M., Kuba M.G., Sánchez V., Smith R.A., et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011, 71:6773-6784. 10.1158/0008-5472.CAN-11-1295.
114. Zhang Y., Moerkens M., Ramaiahgari S., de Bont H., Price L., Meerman J., et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. BCR 2011, 13:R52. 10.1186/bcr2883.
115. Song R.X., Barnes C.J., Zhang Z., Bao Y., Kumar R., Santen R.J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2076-2081. 10.1073/pnas.0308334100.
116. Fan P., Agboke F.A., Cunliffe H.E., Ramos P., Jordan V.C. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur. J. Cancer Oxf. Engl. 1990 2014, 50:2866-2876. 10.1016/j.ejca.2014.08.011.
117. Drury S.C., Detre S., Leary A., Salter J., Reis-Filho J., Barbashina V., et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr. Relat. Cancer. 2011, 18:565-577. 10.1530/ERC-10-0046.
118. Assender J.W., Gee J.M.W., Lewis I., Ellis I.O., Robertson J.F.R., Nicholson R.I. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J. Clin. Pathol. 2007, 60:1216-1221. 10.1136/jcp.2006.041616.
119. Elias D., Vever H., Lænkholm A.-V., Gjerstorff M.F., Yde C.W., Lykkesfeldt A.E., et al. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene 2014, 10.1038/onc.2014.138.
120. Oosterkamp H.M., Hijmans E.M., Brummelkamp T.R., Canisius S., Wessels L.F.A., Zwart W., et al. USP9X downregulation renders breast cancer cells resistant to tamoxifen. Cancer Res. 2014, 74:3810-3820. 10.1158/0008-5472.CAN-13-1960.
121. Gökmen-Polar Y., Neelamraju Y., Goswami C.P., Gu X., Nallamothu G., Janga S.C., et al. Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Mod. Pathol. 2014, Off. J. U. S. Can. Acad. Pathol. Inc. 10.1038/modpathol.2014.146.
122. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. 10.1038/nature11412.
123. Leung E.Y., Kim J.E., Askarian-Amiri M., Joseph W.R., McKeage M.J., Baguley B.C. Hormone resistance in two MCF-7 breast cancer cell lines is associated with reduced mTOR signaling, decreased glycolysis, and increased sensitivity to cytotoxic drugs. Womens Cancer 2014, 4:21. 10.3389/fonc.2014.00221.
124. Nass N., Brömme H.-J., Hartig R., Korkmaz S., Sel S., Hirche F., et al. Differential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells. PLoS ONE 2014, 9:101473. 10.1371/journal.pone.0101473.
125. Zhou Y., Yau C., Gray J.W., Chew K., Dairkee S.H., Moore D.H., et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7:59. 10.1186/1471-2407-7-59.
126. Yde C.W., Emdal K.B., Guerra B., Lykkesfeldt A.E. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res. Treat. 2012, 135:67-78. 10.1007/s10549-012-2053-1.
127. Ott C., Jacobs K., Haucke E., Navarrete Santos A., Grune T., Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014, 2:411-429. 10.1016/j.redox.2013.12.016.
128. Bachmeier B.E., Nerlich A.G., Rohrbach H., Schleicher E.D., Friess U. Maillard products as biomarkers in cancer. Ann. N.Y. Acad. Sci. 2008, 1126:283-287. 10.1196/annals.1433.057.
129. Chiavarina B., Nokin M.-J., Durieux F., Bianchi E., Turtoi A., Peulen O., et al. Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget 2014, 5:5472-5482.
130. Thornalley P.J., Rabbani N. Glyoxalase in tumourigenesis and multidrug resistance. Semin. Cell Dev. Biol. 2011, 22:318-325. 10.1016/j.semcdb.2011.02.006.
131. Antognelli C., Mezzasoma L., Fettucciari K., Talesa V.N. A novel mechanism of methylglyoxal cytotoxicity in prostate cancer cells. Int. J. Biochem. Cell Biol. 2013, 45:836-844. 10.1016/j.biocel.2013.01.003.
132. Arumugam T., Logsdon C.D. S100P: a novel therapeutic target for cancer. Amino Acids 2011, 41:893-899. 10.1007/s00726-010-0496-4.
133. Lata K., Mukherjee T.K. Knockdown of receptor for advanced glycation end products attenuate 17α-ethinyl-estradiol dependent proliferation and survival of MCF-7 breast cancer cells. Biochim. Biophys. Acta 2014, 1840:1083-1091. 10.1016/j.bbagen.2013.11.014.